These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption. Phelps KR; Mason DL Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023 [TBL] [Abstract][Full Text] [Related]
23. Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study. di Giuseppe R; Kühn T; Hirche F; Buijsse B; Dierkes J; Fritsche A; Kaaks R; Boeing H; Stangl GI; Weikert C PLoS One; 2015; 10(7):e0133580. PubMed ID: 26193703 [TBL] [Abstract][Full Text] [Related]
24. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404 [TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor 23 is associated with risk of intracerebral hemorrhage. Svensson EH; Söderholm M Eur J Neurol; 2022 Jan; 29(1):114-120. PubMed ID: 34379844 [TBL] [Abstract][Full Text] [Related]
26. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. Wolf M; Molnar MZ; Amaral AP; Czira ME; Rudas A; Ujszaszi A; Kiss I; Rosivall L; Kosa J; Lakatos P; Kovesdy CP; Mucsi I J Am Soc Nephrol; 2011 May; 22(5):956-66. PubMed ID: 21436289 [TBL] [Abstract][Full Text] [Related]
28. Abnormalities in renal tubular phosphate handling in children with sickle cell disease. Raj VM; Freundlich M; Hamideh D; Alvarez O; Seeherunvong W; Abitbol C; Katsoufis C; Chandar J; Ruiz P; Zilleruelo G Pediatr Blood Cancer; 2014 Dec; 61(12):2267-70. PubMed ID: 25132581 [TBL] [Abstract][Full Text] [Related]
29. Fibroblast Growth Factor-23 and a Vegetarian Diet. Anand S; Jagannathan R; Gupta R; Mohan S; Prabhakaran D; Wolf M J Ren Nutr; 2020 Nov; 30(6):503-508. PubMed ID: 32247648 [TBL] [Abstract][Full Text] [Related]
30. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients. Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073 [TBL] [Abstract][Full Text] [Related]
31. Serum albumin levels are associated with cardioembolic and cryptogenic ischemic strokes: Northern Manhattan Study. Xu WH; Dong C; Rundek T; Elkind MS; Sacco RL Stroke; 2014 Apr; 45(4):973-8. PubMed ID: 24549868 [TBL] [Abstract][Full Text] [Related]
32. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826 [TBL] [Abstract][Full Text] [Related]
33. Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Semba RD; Fink JC; Sun K; Cappola AR; Dalal M; Crasto C; Ferrucci L; Fried LP Clin J Am Soc Nephrol; 2012 Jan; 7(1):85-91. PubMed ID: 22076875 [TBL] [Abstract][Full Text] [Related]
34. Plasma fibroblast growth factor 23 and risk of cardiovascular disease: results from the EPIC-Germany case-cohort study. di Giuseppe R; Kühn T; Hirche F; Buijsse B; Dierkes J; Fritsche A; Kaaks R; Boeing H; Stangl GI; Weikert C Eur J Epidemiol; 2015 Feb; 30(2):131-41. PubMed ID: 25527370 [TBL] [Abstract][Full Text] [Related]
35. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Lundberg S; Qureshi AR; Olivecrona S; Gunnarsson I; Jacobson SH; Larsson TE Clin J Am Soc Nephrol; 2012 May; 7(5):727-34. PubMed ID: 22383747 [TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor 23, but not parathyroid hormone, is associated with urinary phosphate regulation in patients on peritoneal dialysis. Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Hasegawa S; Tanaka S; Eriguchi M; Nakano T; Masutani K; Ooboshi H; Kitazono T Ther Apher Dial; 2015 Feb; 19(1):73-80. PubMed ID: 25195562 [TBL] [Abstract][Full Text] [Related]
37. FGF23 and the PTH response to paricalcitol in chronic kidney disease. D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599 [TBL] [Abstract][Full Text] [Related]
38. Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study. Jovanovich A; Bùzková P; Chonchol M; Robbins J; Fink HA; de Boer IH; Kestenbaum B; Katz R; Carbone L; Lee J; Laughlin GA; Mukamal KJ; Fried LF; Shlipak MG; Ix JH J Clin Endocrinol Metab; 2013 Aug; 98(8):3323-31. PubMed ID: 23771921 [TBL] [Abstract][Full Text] [Related]
39. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. Mehta R; Cai X; Lee J; Scialla JJ; Bansal N; Sondheimer JH; Chen J; Hamm LL; Ricardo AC; Navaneethan SD; Deo R; Rahman M; Feldman HI; Go AS; Isakova T; Wolf M; JAMA Cardiol; 2016 Aug; 1(5):548-56. PubMed ID: 27434583 [TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. Fliser D; Kollerits B; Neyer U; Ankerst DP; Lhotta K; Lingenhel A; Ritz E; Kronenberg F; ; Kuen E; König P; Kraatz G; Mann JF; Müller GA; Köhler H; Riegler P J Am Soc Nephrol; 2007 Sep; 18(9):2600-8. PubMed ID: 17656479 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]